Skip to main content

Adhansia XR FDA Approval History

Last updated by Judith Stewart, BPharm on March 20, 2019.

FDA Approved: Yes (First approved February 27, 2019)
Brand name: Adhansia XR
Generic name: methylphenidate hydrochloride
Dosage form: Extended-Release Capsules
Company: Adlon Therapeutics L.P.
Treatment for: Attention-Deficit / Hyperactivity Disorder

Adhansia XR (methylphenidate hydrochloride) is an extended-release capsule formulation of the approved central nervous system (CNS) stimulant methylphenidate indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients six years and older.

Development timeline for Adhansia XR

Mar  1, 2019Approval FDA Approves Adhansia XR (methylphenidate hydrochloride) Extended-Release Capsules for the Treatment of ADHD

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.